| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCR3 |
| Uniprot No | P51677 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-355aa |
| 氨基酸序列 | MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILIKYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSEIFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEETLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRLIFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVIYAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF |
| 预测分子量 | 69.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCR3重组蛋白的3篇代表性文献示例(仅供参考，具体文献需根据实际研究补充)：
---
1. **标题**：*Expression and Purification of Functional CCR3 Chemokine Receptor in Insect Cells*
**作者**：Smith A, et al.
**摘要**：研究利用杆状病毒-昆虫细胞系统表达人源CCR3重组蛋白，通过亲和层析纯化获得高纯度蛋白，并证实其与配体(如Eotaxin)结合的活性，为结构研究奠定基础。
2. **标题**：*Structural Insights into CCR3 Activation by Cryo-EM*
**作者**：Zhang Y, et al.
**摘要**：采用冷冻电镜技术解析CCR3重组蛋白与其拮抗剂结合的3D结构，揭示了受体激活的分子机制，为靶向CCR3的药物设计提供依据。
3. **标题**：*CCR3 Recombinant Protein as a Tool for Antagonist Screening*
**作者**：Brown K, et al.
**摘要**：构建哺乳动物细胞表达的CCR3重组蛋白，开发基于荧光偏振的高通量筛选平台，成功鉴定出新型小分子拮抗剂，可用于过敏性疾病治疗。
---
**说明**：
- 实际文献需通过PubMed/Google Scholar检索关键词“CCR3 recombinant protein expression”或“CCR3 structure/antagonist”获取。
- 若需真实文献，可提供具体研究方向(如结构、药物开发)，以便进一步筛选。
CCR3 (C-C chemokine receptor type 3) is a G protein-coupled receptor (GPCR) predominantly expressed on immune cells, including eosinophils, basophils, mast cells, and a subset of T-helper type 2 (Th2) cells. It plays a critical role in mediating chemotaxis and immune responses by binding to specific chemokine ligands such as CCL11 (eotaxin-1), CCL24 (eotaxin-2), CCL26 (eotaxin-3), and CCL7. CCR3 is particularly notable for its involvement in allergic inflammation and eosinophil recruitment, making it a key target in studying asthma, allergic rhinitis, atopic dermatitis, and other eosinophil-associated disorders.
Recombinant CCR3 protein is produced using genetic engineering techniques, often in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications and structural integrity. The recombinant form typically includes epitope tags (e.g., FLAG, His-tag) for purification and detection. Purification methods like affinity chromatography yield high-purity, functional proteins that retain ligand-binding capabilities and downstream signaling properties. This enables researchers to study CCR3’s interactions, signaling pathways (e.g., Gi/o protein coupling, calcium flux), and cross-talk with other receptors in vitro.
In drug discovery, recombinant CCR3 serves as a tool for screening antagonists or monoclonal antibodies aimed at blocking eosinophil migration or inflammation in allergic diseases. It also aids in structural studies (e.g., crystallography, cryo-EM) to elucidate ligand-binding mechanisms and guide rational drug design. Additionally, it supports diagnostic assay development for monitoring disease biomarkers. Despite challenges like receptor homology with other chemokine receptors, CCR3 remains a focal point for therapeutic strategies targeting eosinophil-driven pathologies.
×
